• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于预测结肠癌预后和治疗反应的基于趋化因子家族的特征构建与验证

Construction and validation of a chemokine family-based signature for the prediction of prognosis and therapeutic response in colon cancer.

作者信息

Zhang Wen, Kong Defeng, Li Guoliang, Yang Zhenrong, Cheng Shujun, Li Hong, Feng Lin, Zhang Kaitai

机构信息

Department of Immunology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.

National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, College of Bioengineering, Hubei University of Technology, Wuhan 430068, China.

出版信息

Heliyon. 2023 Jun 5;9(6):e16478. doi: 10.1016/j.heliyon.2023.e16478. eCollection 2023 Jun.

DOI:10.1016/j.heliyon.2023.e16478
PMID:37484298
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10360577/
Abstract

The role of chemokines in predicting the prognosis of colon cancer has not been mentioned. Chemokines have been shown to be associated with immune cell chemotaxis and activation, so the expression of chemokine genes in tumor tissue may be related to prognosis. We used a least absolute shrinkage and selection operator (LASSO) model based on chemokine gene families to construct a model that can predict the prognosis of colon cancer patients. We divided patients into high-risk groups and low-risk groups to study the prognosis. Then, we evaluated the relationship between the different risk groups in infiltration of immune cells. It was found that there was less immune cell infiltration in the high-risk group. We conducted a functional enrichment analysis based on model stratification, and explored the biological signal pathways enriched in the high and low-risk groups, which provided ideas for studying the mechanism behind its impact on prognosis. In addition, the chemokine-related gene signature could predict the response of patients to immunotherapy and chemotherapy.

摘要

趋化因子在预测结肠癌预后方面的作用尚未被提及。趋化因子已被证明与免疫细胞趋化和激活有关,因此肿瘤组织中趋化因子基因的表达可能与预后相关。我们使用基于趋化因子基因家族的最小绝对收缩和选择算子(LASSO)模型构建了一个可以预测结肠癌患者预后的模型。我们将患者分为高风险组和低风险组来研究预后。然后,我们评估了不同风险组在免疫细胞浸润方面的关系。发现高风险组的免疫细胞浸润较少。我们基于模型分层进行了功能富集分析,探索了高风险组和低风险组中富集的生物信号通路,这为研究其影响预后背后的机制提供了思路。此外,趋化因子相关基因特征可以预测患者对免疫治疗和化疗的反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eae1/10360577/b5029833e4e1/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eae1/10360577/12cec0ade091/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eae1/10360577/29e0b38079fe/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eae1/10360577/14bda3275a7a/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eae1/10360577/ccd94d69dc34/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eae1/10360577/2f3d891ad4a8/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eae1/10360577/b5029833e4e1/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eae1/10360577/12cec0ade091/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eae1/10360577/29e0b38079fe/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eae1/10360577/14bda3275a7a/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eae1/10360577/ccd94d69dc34/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eae1/10360577/2f3d891ad4a8/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eae1/10360577/b5029833e4e1/gr6.jpg

相似文献

1
Construction and validation of a chemokine family-based signature for the prediction of prognosis and therapeutic response in colon cancer.用于预测结肠癌预后和治疗反应的基于趋化因子家族的特征构建与验证
Heliyon. 2023 Jun 5;9(6):e16478. doi: 10.1016/j.heliyon.2023.e16478. eCollection 2023 Jun.
2
Chemokine- and chemokine receptor-based signature predicts immunotherapy response in female colorectal adenocarcinoma patients.基于趋化因子和趋化因子受体的特征可预测女性结直肠腺癌患者的免疫治疗反应。
Sci Rep. 2023 Dec 4;13(1):21358. doi: 10.1038/s41598-023-48623-2.
3
Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer.新型趋化因子相关长链非编码 RNA 标志物与食管鳞癌的预后、免疫图谱和治疗敏感性相关。
BMC Gastroenterol. 2023 Apr 20;23(1):132. doi: 10.1186/s12876-023-02688-5.
4
Comprehensive alteration-related transcriptomic characterization is involved in immune infiltration and correlated with prognosis and immunotherapy response of bladder cancer.全面的改变相关转录组学特征与膀胱癌的免疫浸润相关,并与预后和免疫治疗反应相关。
Front Immunol. 2022 Jul 26;13:931906. doi: 10.3389/fimmu.2022.931906. eCollection 2022.
5
Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.结肠癌中缺氧相关亚型的鉴定、预后模型的建立及肿瘤微环境浸润特征
Front Genet. 2022 Jun 17;13:919389. doi: 10.3389/fgene.2022.919389. eCollection 2022.
6
An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.一种用于预测结肠腺癌预后、免疫微环境和化疗反应的肿瘤内异质性相关特征
Front Med (Lausanne). 2022 Jul 7;9:925661. doi: 10.3389/fmed.2022.925661. eCollection 2022.
7
Determination of a prediction model for therapeutic response and prognosis based on chemokine signaling-related genes in stage I-III lung squamous cell carcinoma.基于趋化因子信号相关基因的I-III期肺鳞状细胞癌治疗反应和预后预测模型的确定。
Front Genet. 2022 Aug 31;13:921837. doi: 10.3389/fgene.2022.921837. eCollection 2022.
8
A novel chemokine-based signature for prediction of prognosis and therapeutic response in glioma.一种新型趋化因子标志物,用于预测脑胶质瘤的预后和治疗反应。
CNS Neurosci Ther. 2022 Dec;28(12):2090-2103. doi: 10.1111/cns.13944. Epub 2022 Aug 19.
9
A Novel Inflammatory Response-Related Gene Signature Predicts Immune Status and Prognosis of Breast Cancer.一种新型炎症反应相关基因特征可预测乳腺癌的免疫状态和预后。
J Oncol. 2022 Nov 23;2022:5468858. doi: 10.1155/2022/5468858. eCollection 2022.
10
Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma.乳酸代谢相关 lncRNA 对:揭示结直肠腺癌患者免疫景观和介导治疗反应的预后标志物。
Front Immunol. 2022 Jul 11;13:881359. doi: 10.3389/fimmu.2022.881359. eCollection 2022.

引用本文的文献

1
Identification of biomarkers for knee osteoarthritis through clinical data and machine learning models.通过临床数据和机器学习模型识别膝关节骨关节炎的生物标志物
Sci Rep. 2025 Jan 11;15(1):1703. doi: 10.1038/s41598-025-85945-9.

本文引用的文献

1
Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy.癌症免疫治疗中趋化因子导向的肿瘤微环境调节
Int J Mol Sci. 2021 Sep 10;22(18):9804. doi: 10.3390/ijms22189804.
2
A global assessment of recent trends in gastrointestinal cancer and lifestyle-associated risk factors.全球范围内对近期胃肠道癌症的趋势和与生活方式相关的风险因素的评估。
Cancer Commun (Lond). 2021 Nov;41(11):1137-1151. doi: 10.1002/cac2.12220. Epub 2021 Sep 25.
3
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
卡瑞利珠单抗联合化疗对比安慰剂用于治疗晚期或转移性食管鳞癌患者的生存和无进展生存期的影响:ESCORT-1 期随机临床试验。
JAMA. 2021 Sep 14;326(10):916-925. doi: 10.1001/jama.2021.12836.
4
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.帕博利珠单抗联合化疗与单纯化疗一线治疗晚期食管癌(KEYNOTE-590):一项随机、安慰剂对照、III 期研究。
Lancet. 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4.
5
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma.派姆单抗和恩替诺特联合治疗转移性葡萄膜黑色素瘤患者的 PEMDAC 二期研究。
Nat Commun. 2021 Aug 27;12(1):5155. doi: 10.1038/s41467-021-25332-w.
6
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer.新辅助免疫检查点抑制剂治疗非小细胞肺癌后,淋巴结免疫 flares 模拟淋巴结疾病进展。
Nat Commun. 2021 Aug 19;12(1):5045. doi: 10.1038/s41467-021-25188-0.
7
SEMA4D Knockdown Attenuates -Catenin-Dependent Tumor Progression in Colorectal Cancer.SEMA4D 敲低可抑制结直肠癌中β-连环蛋白依赖性肿瘤进展。
Biomed Res Int. 2021 Jul 21;2021:8507373. doi: 10.1155/2021/8507373. eCollection 2021.
8
Single-cell analyses reveal suppressive tumor microenvironment of human colorectal cancer.单细胞分析揭示人类结直肠癌的抑制性肿瘤微环境。
Clin Transl Med. 2021 Jun;11(6):e422. doi: 10.1002/ctm2.422.
9
Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.免疫检查点 B7-H3 蛋白表达与前列腺癌的不良预后和雄激素受体状态相关。
Prostate. 2021 Sep;81(12):838-848. doi: 10.1002/pros.24180. Epub 2021 Jun 14.
10
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.一线纳武利尤单抗联合化疗与单纯化疗治疗晚期胃癌、胃食管交界癌和食管腺癌(CheckMate 649):一项随机、开放标签的3期试验。
Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5.